The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.
Patel, Saroor A
Richardson, Emma K
Syafruddin, Saiful E
Purdue, Mark P
Springer Science and Business Media LLC
MetadataShow full item record
Patel, S. A., Hirosue, S., Rodrigues, P., Vojtasova, E., Richardson, E. K., Ge, J., Syafruddin, S. E., et al. (2022). The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.. Nature, 606 (7916), 999-1006. https://doi.org/10.1038/s41586-022-04809-8
Large-scale human genetic data1-3 have shown that cancer mutations display strong tissue-selectivity, but how this selectivity arises remains unclear. Here, using experimental models, functional genomics and analyses of patient samples, we demonstrate that the lineage transcription factor paired box 8 (PAX8) is required for oncogenic signalling by two common genetic alterations that cause clear cell renal cell carcinoma (ccRCC) in humans: the germline variant rs7948643 at 11q13.3 and somatic inactivation of the von Hippel-Lindau tumour suppressor (VHL)4-6. VHL loss, which is observed in about 90% of ccRCCs, can lead to hypoxia-inducible factor 2α (HIF2A) stabilization6,7. We show that HIF2A is preferentially recruited to PAX8-bound transcriptional enhancers, including a pro-tumorigenic cyclin D1 (CCND1) enhancer that is controlled by PAX8 and HIF2A. The ccRCC-protective allele C at rs7948643 inhibits PAX8 binding at this enhancer and downstream activation of CCND1 expression. Co-option of a PAX8-dependent physiological programme that supports the proliferation of normal renal epithelial cells is also required for MYC expression from the ccRCC metastasis-associated amplicons at 8q21.3-q24.3 (ref. 8). These results demonstrate that transcriptional lineage factors are essential for oncogenic signalling and that they mediate tissue-specific cancer risk associated with somatic and inherited genetic variants.
Article, /631/67/69, /631/208/191, /631/67/70, /631/208/200, /692/699/67/589/1588/1351, /38/32, /38/39, /38/35, /38/89, /38/91, /38/109, /82/58, /13, /13/31, /13/106, /45, /45/15, /45/41, /45/43, /64, /64/60, /59, /59/5, /42, /82/29, /82/80, article
Medical Research Council (MC_UU_12022/7 and MC_UU_12022/10) and Kidney Research UK (RP_033_20170303).
Medical Research Council (MC_UU_12022/7)
Cancer Research UK (C96/A25177)
Kidney Research UK (RP_033_20170303)
European Commission Horizon 2020 (H2020) Marie Sk?odowska-Curie actions (955951)
National Institute for Health Research (NIHRDH-IS-BRC-1215-20014)
External DOI: https://doi.org/10.1038/s41586-022-04809-8
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338610
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com